



**THE 23<sup>rd</sup> TEL-AVIV UNIVERSITY ALZHEIMER'S DISEASE CONFERENCE**  
 Sponsored by the Sagol School of Neuroscience, the Adams Super Center for Brain Studies, and the  
 Rabin Center for Neurobiology, Tel-Aviv University

**June 24-25, 2015**

**Program**

**Lectures will be held at the Lola Auditorium, Faculty of Medicine, Tel-Aviv University Campus**

**WEDNESDAY, JUNE 24, 2015**

08:00 – 08:30 Registration

**Chair: Amos Korczyn, Danny Michaelson**

08:30 - 08:40 **Greetings: Geri Roth, Uri Ashery**

**Session 1 Tau pathology**

**Session in honor of the late Professor Michele Tansella**

**Chair: Joab Chapman, Therese Treves**

08:40 – 09:20 **Johannes Attems (UK)**

Tau-related neurodegeneration

09:20 – 09:40 **Hanna Rosenmann**

CSF tau protein in neurodegenerative diseases

09:40 – 10:00 **Illana Gozes**

Translational tau: From bench to biotech: ADNP/NAP as a case study

10:00 – 10:20 **Ed Stern**

Pathological tau disrupts ongoing network activity

10:20 – 10:40 **Hagit Eldar Finkelman**

GSK-3 interacts with lysosome networking and contributes to neurodegeneration

10:40 – 11:10 **Coffee break**



## Session 2 Animal models

**Chair: Danny Frenkel, Michael Davidson**

11:10 – 11:50 **Manfred Windisch** (Austria)

Focus on tau as therapeutic target: Animal models

11:50 – 12:10 **Shira Knafo** (Spain)

PTEN controls synaptic and cognitive function in AD models

12:10 – 12:30 **Menahem Segal**

Stress and AD in triple tg mice

12:30 – 12:50 **Daniel Segal**

Altered protein glycosylation predicts AD and modulates its pathology

12:50 – 13:10 **Eli Ezrielev**

Teaching an old mouse new tricks

13:10 – 14:00 **Lunch**



## Session 3 Clinical aspects of AD

**Chair: Odelia Elkana , Eli Wertman**

14:00– 14:40 **Asa Abeliovich** (USA)

Epigenetics of AD

14:40 – 15:00 **Shahar Arzy**

What we talk about when we talk about disorientation in patients with dementia:

Neuropsychological, behavioral and functional imaging evidence

15:00– 15:20 **Naomi Nevler**

Revision of the CDR scale

15:20 – 15:40 **Tamara Shiner**

Probing the link between GBA mutations and synucleinopathies

15:40 – 16:00 **Coffee break**



### **Session 3 Continued**

16:00 – 16:20 **Yvonne Freund-Levi (Sweden)**

Relation between APOE4 alleles and potential omega-3 fatty acid treatment effects on neuropsychiatric and cognitive symptoms in AD - the OmegAD Study a RCT.

16:20 – 16:40 **Ralph Laufer**

Teva strategy in neuroscience

### **Session 4 Swift 5 minutes Student Presentations**

**Chair: Einor Ben Assayag, Danny Offen**

16:40 – 17:15 **Shoshik Amram**

Transforming Growth Factor  $\beta 1$  signaling in astrocytes mediates astrocytes activity in AD

**Anat Boehm-Cagan**

ABCA1 agonist peptides: a new therapeutic avenue for the treatment of AD

**Korin Ben**

Effects of central cholinergic deficits on immunity

**Ishai Luz**

An anti-apoE4 specific monoclonal antibody counteracts the pathological effects of *apoE4* in *vivo*

**Meytal Raizes**

Higher normal blood glucose level are associated with decreased processing speed in high functioning young elderly


**Ronit Shapira**

Hyperbaric oxygen therapy ameliorates the pathophysiology of AD mouse model

**Shira Simonovitch**

Impaired autophagy in ApoE4 astrocytes

**THURSDAY, JUNE 25, 2015****Session 5 Neuroinflammation****Session in honor of Mrs Joni Berry Eichenbaum****Chair: Ramit Ravona, Orly Weinreb**

- 08:30 – 09:10    **Howard Weiner (USA)**  
Immune mechanisms in AD
- 09:10– 09:30    **Alon Monsonego**  
Therapeutic translation of brain immune interactions
- 09:30 – 09:50    **Reuven Stein**  
Targeting CD38 attenuates AD pathology in AD-prone mice
- 09:50 – 10:10    **Danny Frenkel**  
**Impairment in astrocyte activity accelerates disease progression in AD mouse model**
- 10:10 – 10:30    **Assaf Ezra**  
Multifunctional effect of human serum albumin towards neuroprotection in AD
- 10:30 – 11:00    **Coffee break**    

**Session 6 New approaches to mitigate AD pathology****Chair: Silvia Mandel, Beka Salomon**

- 11:00 – 11:40    **Gil Rabinovici (USA)**  
Imaging tau in humans
- 11:40 – 12:00    **Gad Marshall (USA)**  
Imaging biomarker correlates of neuropsychiatric symptoms in early AD
- 12:00 – 12:20    **Galit Wainstein**  
Serum BDNF and risk of dementia
- 12:20 – 12:40    **Israel Aharony**  
A novel Caspase-6 inhibitor as a potential therapy for AD
- 12:40 – 13:00    **Uri Ashery**

## New approaches to mitigate AD pathology

13:00 – 14:00

**Lunch****Session 7 Treatment****Chair: Ruth Gabizon, Zeev Meiner**

14:00 – 14:40

**Mark Pepys (UK)**

Therapeutic targeting of serum amyloid P component in AD

14:40 – 15:00

**Abraham Fisher**

A novel ultra-potent GPCR-Sigma1 receptor agonist targets major hallmarks of AD

15:00 – 15:20

**Liu Wei**

Novel multifunctional ChE-MAO inhibitors for treatment of AD

15:20 - 15:30

**Danny Michaelson**

Development of APOE4 targeted treatment

15:30 – 15:50

**Eyal Bar Or**

Experience with using TMS combined with cognitive training in Neuronix Israeli AD clinic

15:50 – 16:10

**Coffee break**

16:10 – 16:30

**Gerardo Lederkremer**

Genesis of ER stress in Huntington's and other neurodegenerative diseases

16:30 – 16:50

**Amos Korczyn**

Risk factors for AD: Implications for therapy

16:50 - 17:30

**Round table on treatment and Award for best swift student presentations****Supported by: Avraham Pharma, Enzymotec, NBT, Neuronix, Novartis, Teva****Avraham**  
P H A R M A**Enzymotec**  
Delivering Lipids**NBT**  
New Biotechnology Ltd**NEURONIX**  
INTEGRATING NEUROLOGICAL SOLUTIONS**NOVARTIS**